Literature DB >> 20616797

Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia.

Michael G Kharas1, Christopher J Lengner, Fatima Al-Shahrour, Lars Bullinger, Brian Ball, Samir Zaidi, Kelly Morgan, Winnie Tam, Mahnaz Paktinat, Rachel Okabe, Maricel Gozo, William Einhorn, Steven W Lane, Claudia Scholl, Stefan Fröhling, Mark Fleming, Benjamin L Ebert, D Gary Gilliland, Rudolf Jaenisch, George Q Daley.   

Abstract

RNA-binding proteins of the Musashi (Msi) family are expressed in stem cell compartments and in aggressive tumors, but they have not yet been widely explored in the blood. Here we demonstrate that Msi2 is the predominant form expressed in hematopoietic stem cells (HSCs), and its knockdown leads to reduced engraftment and depletion of HSCs in vivo. Overexpression of human MSI2 in a mouse model increases HSC cell cycle progression and cooperates with the chronic myeloid leukemia-associated BCR-ABL1 oncoprotein to induce an aggressive leukemia. MSI2 is overexpressed in human myeloid leukemia cell lines, and its depletion leads to decreased proliferation and increased apoptosis. Expression levels in human myeloid leukemia directly correlate with decreased survival in patients with the disease, thereby defining MSI2 expression as a new prognostic marker and as a new target for therapy in acute myeloid leukemia (AML).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616797      PMCID: PMC3090658          DOI: 10.1038/nm.2187

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  30 in total

1.  The neural RNA-binding protein Musashi1 translationally regulates mammalian numb gene expression by interacting with its mRNA.

Authors:  T Imai; A Tokunaga; T Yoshida; M Hashimoto; K Mikoshiba; G Weinmaster; M Nakafuku; H Okano
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

2.  Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.

Authors:  Huining Kang; I-Ming Chen; Carla S Wilson; Edward J Bedrick; Richard C Harvey; Susan R Atlas; Meenakshi Devidas; Charles G Mullighan; Xuefei Wang; Maurice Murphy; Kerem Ar; Walker Wharton; Michael J Borowitz; W Paul Bowman; Deepa Bhojwani; William L Carroll; Bruce M Camitta; Gregory H Reaman; Malcolm A Smith; James R Downing; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

3.  RNA-binding protein Musashi family: roles for CNS stem cells and a subpopulation of ependymal cells revealed by targeted disruption and antisense ablation.

Authors:  Shin-ichi Sakakibara; Yuki Nakamura; Tetsu Yoshida; Shinsuke Shibata; Masato Koike; Hiroshi Takano; Shuichi Ueda; Yasuo Uchiyama; Tetsuo Noda; Hideyuki Okano
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-29       Impact factor: 11.205

4.  MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.

Authors:  Brian J P Huntly; Hirokazu Shigematsu; Kenji Deguchi; Benjamin H Lee; Shinichi Mizuno; Nicky Duclos; Rebecca Rowan; Sonia Amaral; David Curley; Ifor R Williams; Koichi Akashi; D Gary Gilliland
Journal:  Cancer Cell       Date:  2004-12       Impact factor: 31.743

5.  A novel gene, MSI2, encoding a putative RNA-binding protein is recurrently rearranged at disease progression of chronic myeloid leukemia and forms a fusion gene with HOXA9 as a result of the cryptic t(7;17)(p15;q23).

Authors:  Aikaterini Barbouti; Mattias Höglund; Bertil Johansson; Carin Lassen; Per-Gunnar Nilsson; Anne Hagemeijer; Felix Mitelman; Thoas Fioretos
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

6.  Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia.

Authors:  Lars Bullinger; Konstanze Döhner; Eric Bair; Stefan Fröhling; Richard F Schlenk; Robert Tibshirani; Hartmut Döhner; Jonathan R Pollack
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

Review 7.  Disruption of differentiation in human cancer: AML shows the way.

Authors:  Daniel G Tenen
Journal:  Nat Rev Cancer       Date:  2003-02       Impact factor: 60.716

8.  Cancerous stem cells can arise from pediatric brain tumors.

Authors:  Houman D Hemmati; Ichiro Nakano; Jorge A Lazareff; Michael Masterman-Smith; Daniel H Geschwind; Marianne Bronner-Fraser; Harley I Kornblum
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-26       Impact factor: 11.205

9.  The RNA binding protein Musashi1 regulates apoptosis, gene expression and stress granule formation in urothelial carcinoma cells.

Authors:  Parvaneh Nikpour; Modjtaba Emadi Baygi; Christine Steinhoff; Christiane Hader; Anna C Luca; Seyed J Mowla; Wolfgang A Schulz
Journal:  J Cell Mol Med       Date:  2010-05-14       Impact factor: 5.310

10.  Lin28 promotes transformation and is associated with advanced human malignancies.

Authors:  Srinivas R Viswanathan; John T Powers; William Einhorn; Yujin Hoshida; Tony L Ng; Sara Toffanin; Maureen O'Sullivan; Jun Lu; Letha A Phillips; Victoria L Lockhart; Samar P Shah; Pradeep S Tanwar; Craig H Mermel; Rameen Beroukhim; Mohammad Azam; Jose Teixeira; Matthew Meyerson; Timothy P Hughes; Josep M Llovet; Jerald Radich; Charles G Mullighan; Todd R Golub; Poul H Sorensen; George Q Daley
Journal:  Nat Genet       Date:  2009-05-31       Impact factor: 38.330

View more
  165 in total

1.  Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer.

Authors:  Chunxiao Wu; Alexander W Wyatt; Anna V Lapuk; Andrew McPherson; Brian J McConeghy; Robert H Bell; Shawn Anderson; Anne Haegert; Sonal Brahmbhatt; Robert Shukin; Fan Mo; Estelle Li; Ladan Fazli; Antonio Hurtado-Coll; Edward C Jones; Yaron S Butterfield; Faraz Hach; Fereydoun Hormozdiari; Iman Hajirasouliha; Paul C Boutros; Robert G Bristow; Steven Jm Jones; Martin Hirst; Marco A Marra; Christopher A Maher; Arul M Chinnaiyan; S Cenk Sahinalp; Martin E Gleave; Stanislav V Volik; Colin C Collins
Journal:  J Pathol       Date:  2012-03-21       Impact factor: 7.996

2.  Autoregulation of Musashi1 mRNA translation during Xenopus oocyte maturation.

Authors:  Karthik Arumugam; Melanie C Macnicol; Angus M Macnicol
Journal:  Mol Reprod Dev       Date:  2012-07-09       Impact factor: 2.609

3.  A cancer fate in the hands of a samurai.

Authors:  Malcolm A S Moore
Journal:  Nat Med       Date:  2010-09       Impact factor: 53.440

Review 4.  Context-dependent regulation of Musashi-mediated mRNA translation and cell cycle regulation.

Authors:  Melanie C MacNicol; Chad E Cragle; Angus M MacNicol
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

5.  Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML.

Authors:  Kenneth D Gibbs; Astraea Jager; Oliver Crespo; Yury Goltsev; Angelica Trejo; Chase E Richard; Garry P Nolan
Journal:  Cell Stem Cell       Date:  2012-02-03       Impact factor: 24.633

6.  High expression of transcription factor 4 (TCF4) is an independent adverse prognostic factor in acute myeloid leukemia that could guide treatment decisions.

Authors:  Florentien E M in 't Hout; Bert A van der Reijden; Davide Monteferrario; Joop H Jansen; Gerwin Huls
Journal:  Haematologica       Date:  2014-08-22       Impact factor: 9.941

7.  Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program.

Authors:  Sun-Mi Park; Mithat Gönen; Ly Vu; Gerard Minuesa; Patrick Tivnan; Trevor S Barlowe; James Taggart; Yuheng Lu; Raquel P Deering; Nir Hacohen; Maria E Figueroa; Elisabeth Paietta; Hugo F Fernandez; Martin S Tallman; Ari Melnick; Ross Levine; Christina Leslie; Christopher J Lengner; Michael G Kharas
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

Review 8.  Stem Cells, Cancer, and MUSASHI in Blood and Guts.

Authors:  Michael G Kharas; Christopher J Lengner
Journal:  Trends Cancer       Date:  2017-04-08

Review 9.  Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets.

Authors:  Alexander E Kudinov; John Karanicolas; Erica A Golemis; Yanis Boumber
Journal:  Clin Cancer Res       Date:  2017-01-31       Impact factor: 12.531

10.  Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML.

Authors:  Elizabeth Heyes; Luisa Schmidt; Gabriele Manhart; Thomas Eder; Ludovica Proietti; Florian Grebien
Journal:  Leukemia       Date:  2021-02-23       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.